Get the Stockscreener App
1.874
0.81%
0.014
Ocugen Inc stock is traded at $1.874, with a volume of 8.69M.
It is up +0.81% in the last 24 hours and up +17.92% over the past month.
Ocugen Inc company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve health and offer hope for patients across the globe. The company's pipeline includes Modifier Gene Therapy Platform, Novel Biologic Therapy for Retinal Diseases, Regenerative Medicine Cell Therapy Platform, Inhaled Mucosal Vaccine Platform. The company is developing a modifier gene therapy platform designed to fulfill unmet medical needs related to retinal diseases, including inherited retinal diseases ("IRDs"), such as RP, LCA, Stargardt disease, and multifactorial diseases such as dAMD and Geographic Atrophy ("GA").
See More
Previous Close:
$1.86
Open:
$1.82
24h Volume:
8.69M
Relative Volume:
1.90
Market Cap:
$613.73M
Revenue:
-
Net Income/Loss:
$-63.08M
P/E Ratio:
-6.9407
EPS:
-0.27
Net Cash Flow:
$-72.53M
1W Performance:
+17.92%
1M Performance:
+17.92%
6M Performance:
+80.29%
1Y Performance:
+207.33%
1-Day Range:
$1.81
$1.94
1-Week Range:
$1.56
$1.94
52-Week Range:
$0.515
$1.96
Ocugen Inc Stock (OCGN) Company Profile
Name
Ocugen Inc
Sector
Industry
Phone
484-328-4701
Address
11 GREAT VALLEY PARKWAY, MALVERN, PA
Compare OCGN vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
OCGN
Ocugen Inc
|
1.875 | 608.82M | 0 | -63.08M | -72.53M | -0.27 |
|
VRTX
Vertex Pharmaceuticals Inc
|
479.00 | 122.71B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
768.74 | 82.91B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
771.71 | 50.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
330.13 | 43.42B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
322.40 | 38.98B | 4.98B | 69.60M | 525.67M | 0.5198 |
Ocugen Inc Stock (OCGN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-15-24 | Initiated | Maxim Group | Buy |
| Mar-01-23 | Upgrade | Chardan Capital Markets | Neutral → Buy |
| Aug-23-22 | Initiated | Mizuho | Buy |
| Jun-15-22 | Resumed | ROTH Capital | Buy |
| Jun-02-22 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-26-21 | Initiated | Noble Capital Markets | Outperform |
| Jun-11-21 | Downgrade | ROTH Capital | Buy → Neutral |
| May-07-21 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Feb-09-21 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Feb-04-21 | Upgrade | H.C. Wainwright | Neutral → Buy |
View All
Ocugen Inc Stock (OCGN) Latest News
Why Did OCGN Stock Rise Today? - Asianet Newsable
Investment Report: Is Ocugen Inc undervalued by DCF analysisJuly 2025 Macro Moves & Free Real-Time Volume Trigger Notifications - baoquankhu1.vn
Ocugen to Host March 4 Call on Q4 and Full-Year 2025 Results - MyChesCo
Risk Analysis: Is Ocugen Inc a cyclical or defensive stockWeekly Stock Summary & AI Enhanced Trading Signals - baoquankhu1.vn
Will Ocugen Inc. stock split again soonJuly 2025 Weekly Recap & Weekly Top Stock Performers List - mfd.ru
Profit Review: Is RILY attractive at current valuationWeekly Trade Review & Technical Analysis for Trade Confirmation - baoquankhu1.vn
Ocugen appoints Rita Johnson-Greene as chief financial officer - MSN
Ocugen, Inc. to Host Conference Call for Fourth Quarter and Full Year 2025 Financial Results on March 4, 2026 - Quiver Quantitative
Ocugen to Host Conference Call on Wednesday, March 4, 2026 at 8:30 A.M. ET to Discuss Business Updates and Fourth Quarter and Full Year 2025 Financial Results - The Manila Times
Ocugen to Host Conference Call on Wednesday, March 4, 2026 - GlobeNewswire
Ocugen (NASDAQ:OCGN) Trading 2.1% HigherTime to Buy? - MarketBeat
Ocugen Appoints Rita Johnson-Greene as Chief Financial Officer - MyChesCo
How cyclical is Ocugen Inc. (2H51) stock compared to rivalsMarket Sentiment Summary & Daily Entry Point Trade Alerts - mfd.ru
Is Ocugen Inc. stock attractive for ETFsJuly 2025 Volume & Short-Term Trading Alerts - mfd.ru
Aug EndMonth: Is Ocugen Inc a momentum stockJuly 2025 Market Mood & Risk Controlled Stock Alerts - baoquankhu1.vn
Stock Quote & Chart - Ocugen, Inc.
Highs Report: Is Ocugen Inc a cyclical or defensive stock2025 Retail Activity & Free Risk Controlled Daily Trade Plans - baoquankhu1.vn
What The Latest Developments Mean For Ocugen’s Changing Valuation Story - Yahoo Finance
Ocugen foresees gene-agnostic therapies advancing blindness treatment - Traders Union
Can Ocugen Inc. weather a recessionJuly 2025 Selloffs & AI Enhanced Trading Signals - mfd.ru
Ocugen Bolsters Leadership Ahead of Critical Regulatory Milestone - AD HOC NEWS
Ocugen appoints Rita Johnson-Greene as new CFO By Investing.com - Investing.com South Africa
Ocugen appoints Rita Johnson-Greene as chief financial officer By Investing.com - Investing.com Canada
Ocugen Appoints Rita Johnson-Greene as New Chief Financial Officer - TipRanks
Ocugen (OCGN) Appoints New CFO, Shares Rise - GuruFocus
Ocugen (OCGN) Appoints New CFO to Strengthen Leadership Team - GuruFocus
Ocugen, Inc. Appoints New Chief Financial Officer - TradingView
Ocugen Names Rita Johnson-Greene as CFO - marketscreener.com
Ocugen appoints Rita Johnson-Greene as new CFO - Investing.com
Ocugen Appoints Rita Johnson-Greene to Chief Financial Officer - citybiz
Ocugen, Inc. Appoints Rita Johnson-Greene as Chief Financial Officer - Quiver Quantitative
Ocugen Appoints Rita Johnson-Greene To Chief Financial Officer - TradingView
Ocugen grants CEO new performance-based equity award - MSN
Wall Street Recap: Can Ocugen Inc be recession proof2025 Price Action Summary & Free Expert Approved Momentum Trade Ideas - baoquankhu1.vn
Breakout Move: Will Ocugen Inc stock recover after earningsJuly 2025 Levels & Real-Time Market Trend Scan - baoquankhu1.vn
Ocugen’s Gene Therapy Progress and Funding Extend Runway - AD HOC NEWS
Ocugen Shares Stabilize Following Recent Equity Offering - AD HOC NEWS
Trade Report: Can Ocugen Inc be recession proofWeekly Investment Summary & Verified Swing Trading Watchlist - baoquankhu1.vn
Ocugen Stock Lifts Retail Investor Confidence As Q4 Revenue Crushes Estimates - MSN
Ocugen’s Gene Therapy OCU410ST Continues to Show Efficacy in Phase 1 Stargardt Disease Trial - CGTLive®
Ocugen Doses First Patient in Pivotal Trial for Stargardt Gene Therapy - MSN
Ocugen prices $22.5M common stock offering at $1.50 per share - MSN
What are analysts price targets for Ocugen IncJuly 2025 Volume & Long Hold Capital Preservation Tips - baoquankhu1.vn
Valuation Update: Can Belite Bio Inc Depositary Receipt deliver alphaWeekly Market Outlook & Smart Allocation Stock Tips - baoquankhu1.vn
RSI Check: Can Ocugen Inc weather a recessionWeekly Trading Summary & Community Consensus Trade Alerts - baoquankhu1.vn
Ocugen’s Gene Therapy Candidate Shows Promise in Early-Stight Loss Trial - AD HOC NEWS
Ocugen’s Stargardt Gene Therapy OCU410ST Provides +6-Letter Gain in BCVA-Evaluable Patients in Phase 1 Trial - NeurologyLive
Ocugen Inc Stock (OCGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.66%
0.99%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):